Clinical Trials Directory

In this study, people are placed into one of two groups based on certain features found in their genes. The first group, called Cohort 1, includes people who have low‑risk genetic signs. To be in this group, a person must have a mutated IGHV gene, must not have a 17p deletion, and must not have a TP53 mutation. All three conditions must be true. People in this group will first take a medicine called acalabrutinib for two cycles. After that, they will take a combination of acalabrutinib and venetoclax, called AV, for twelve more cycles. The second group, called Cohort 2, includes people who have any high‑risk genetic signs. This may include having an unmutated IGHV gene, a 17p deletion, a TP53 mutation, or a mix of these.

We are doing this study to find out if a program called AYA STEPS has a positive benefit for young people who are treated for cancer. We want to know how well this program can help cancer survivors younger than 40 manage any physical or emotional symptoms they have after treatment, and we also want to see if the program can help them be more engaged with follow-up care.

This study includes a screening visit, a treatment period lasting 8 to 12 weeks, and a follow-up. During the screening, you will have a medical exam, and information about your health and background will be collected from your hospital records. If you qualify and choose to join, you will take Vitamin B6 once a day for 8 to 12 weeks. You and a caregiver will receive study questionnaires electronically. These will be sent within 7 days after you join the study, before you start taking Vitamin B6, and again after your follow-up visit. You will have up to 14 days to complete each set of questionnaires. There is no special visit at the end of treatment. The study ends once you finish the final set of questionnaires after taking Vitamin B6.

We are doing this study to find out whether certain immunotherapy drug combinations with and without chemotherapy given before and after surgery for mesothelioma can help prevent the tumor from coming back. The two immunotherapy drugs, durvalumab and tremelimumab, are called immune checkpoint inhibitors and are used to activate the immune system against cancer. Immune checkpoint inhibitors are now approved for mesothelioma for patients who cannot undergo surgery, but they are not approved prior to surgery. The chemotherapy drugs (cisplatin or carboplatin and pemetrexed) are standard options for the treatment of mesothelioma.

We are doing this study to find out if an investigational drug called TP-3654 (the study drug) is a safe and effective treatment for myelofibrosis. The study drug will be tested at different doses to find out what effects, if any, it has on myelofibrosis.

This study has two parts. In the first part, researchers test different dose levels of a new medicine called BBO 11818 to find the safest and best dose. Some people will receive BBO 11818 by itself, while others will receive it together with other cancer medicines. The treatment group depends on the type of cancer and the specific KRAS gene change a person has. In the second part, more people will receive the dose that was found to be safe in the first part. Researchers will study BBO 11818 by itself and in combination with other treatments in different groups of patients. The goal is to learn more about how safe the medicine is, what side effects it may cause, and whether it can help slow or shrink cancers with specific KRAS gene changes.

The study has 4 parts: screening, taking the study drug, stopping the drug, and follow-up. You’ll get tests like blood work, heart checks, and scans. You’ll be randomly given one of two medicines: BGB-16673 or Pirtobrutinib, both taken once a day. After stopping the medicine, you’ll return for a check-up in about a month. If your cancer hasn’t gotten worse, you’ll visit every 6 months. If it has, the study team will check on you by phone or email. The whole study may last about 3 years with around 13 visits.

Before joining the study, people will have health tests such as physical exams, blood and urine tests, heart tests, scans, and testing of their tumor to see if they can participate. If they qualify, they will be placed into a treatment group by chance. One group will receive a new study medicine called BGB 43395 together with a medicine called letrozole. Other groups will receive approved breast cancer medicines called abemaciclib, palbociclib, or ribociclib together with letrozole. All of the study medicines are taken by mouth. During the study, participants will have regular clinic visits, blood tests, heart monitoring, imaging scans, questionnaires, and keep a daily record of their medicines. The study may last for several years, and doctors will continue to check on participants even after the study treatment ends.